Terms ending in 2036
Every in-force patent on Araxes Pharma LLC's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,246,424 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US RE50,490 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · Low confidence | Araxes Pharma LLC | In force | Low confidence | |
| US 10,428,064 | Fused-Tricyclic Inhibitors of Kras and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,858,343 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,647,703 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,730,867 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,875,842 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,689,356 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,975,071 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,414,757 | 2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| 2 more term ends in 2036 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.